NCT04944303View on ClinicalTrials.gov

The Feasibility of Sugammadex for General Anesthesia in Patients Undergoing Kidney and Pancreas Transplantation Surgery

NACompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

December 18, 2020

Primary Completion Date

April 21, 2021

Study Completion Date

April 21, 2021

Conditions
Surgery
Interventions
DRUG

Sugammadex

Sugammadex is a modified γ-cyclodextrin designed selectively to reverse the effects of the neuromuscular blocking agents (NMBAs) rocuronium and vecuronium

DRUG

Normal saline

Equal doseage of normal saline was injected to reverse the NMB.

Trial Locations (2)

510260

The Second Affiliated Hospital,Guangzhou Medical University, Guangzhou

Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

Second Affiliated Hospital of Guangzhou Medical University

OTHER

NCT04944303 - The Feasibility of Sugammadex for General Anesthesia in Patients Undergoing Kidney and Pancreas Transplantation Surgery | Biotech Hunter | Biotech Hunter